TP53

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)

Retrieved on: 
Lunedì, Aprile 15, 2024
SLATE, Mutation, Safety, HLA, Trial of the century, National Cancer Institute, Vaccine, Gritstone bio, Human, Antigen presentation, BRAF, Oncogene, Patient, TP53, NCI, CTNNB1, Pharmaceutical industry

EMERYVILLE, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that a paper detailing the development of its “off-the-shelf” neoantigen platform, SLATE, recently published in Nature Medicine. The paper, “A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results,” describes a novel immunodominance hierarchy of tumor neoantigens (including KRAS) that Gritstone discovered in Phase 1 translational studies and leveraged to develop SLATE-KRAS, a “pure” KRAS-directed candidate that demonstrated superior immunogenicity to the initial version in a subsequent Phase 2 study and is currently being evaluated in a novel cell therapy-vaccine combination study run by Steven A. Rosenberg of the National Cancer Institute (NCT06253520).

Key Points: 
  • "Our team’s innovative work to develop, optimize and validate SLATE positions Gritstone with two promising platforms to execute against our neoantigen-directed approach to oncology.
  • Neoantigens were identified using Gritstone bio’s proprietary neoantigen prediction platform, EDGETM, and selected based on shared mutation and matched HLA frequencies in patient populations with solid tumors.
  • These data led to the development of SLATE-KRAS, a vaccine focused on KRAS-derived neoantigens that subsequently was evaluated in the Phase 2 portion of the clinical study.
  • Initial Phase 2 data suggesting an increased vaccine induced T cell response were presented in September 2022 ( press release ).

Affini-T Therapeutics to Present Data From Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on: 
Mercoledì, Maggio 1, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Cancer, HLA, MD, Cell, Data, Patient, TP53, Gene, Society, LOH, MHC, LVV, Annual general meeting, TCR, Therapy, Vaccine

Affini-T Therapeutics, Inc. , a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its preclinical gene edited HLA-A*11:01 KRAS G12D (AFNT-212) and HLA-A*02:01 TP53 R175H T Cell Receptor (TCR) T cell therapy products for the treatment of solid cancers will be presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting held in Baltimore, MD May 7-11.

Key Points: 
  • Affini-T Therapeutics, Inc. , a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that data from its preclinical gene edited HLA-A*11:01 KRAS G12D (AFNT-212) and HLA-A*02:01 TP53 R175H T Cell Receptor (TCR) T cell therapy products for the treatment of solid cancers will be presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting held in Baltimore, MD May 7-11.
  • “Our mission is to address the significant unmet needs of patients with hard-to-treat solid tumors by advancing precision immunotherapies that target oncogenic driver mutations,” said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics.
  • “We believe that our non-viral targeted knock-in platform, THRIVETM, will enable us to cost-effectively engineer safe and effective T cell therapy products.
  • “TCR based therapies targeting cancer driver mutations recognize the human leukocyte antigen (HLA)/peptide complex on tumor cells,” said Dirk Nagorsen, M.D., Chief Medical Officer at Affini-T Therapeutics.

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Domenica, Aprile 7, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Toxicity, TP53, Patient, Lung, Arginine, AACR, Cholangiocarcinoma, Therapy, TRAC, Pancreas, CRISPR, TCR, Vaccine

Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that management is presenting data from the company’s oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H at this year’s American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.

Key Points: 
  • Affini-T Therapeutics, Inc ., a precision immunotherapy company unlocking the power of T cells against oncogenic driver mutations, today announced that management is presenting data from the company’s oncogenic driver programs targeting HLA-A*11:01 KRAS G12D and HLA-A*02:01 p53 R175H at this year’s American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego.
  • “We are also proud to present preclinical data from our cell therapy targeting KRAS G12D, which highlights the promising potential of our proprietary non-viral knock-in THRIVE™ platform.
  • The study supports the planned clinical investigation of the novel KRAS G12D mutant TCR-engineered CD4+ and CD8+ T cell therapy in 2024.
  • These data support the planned clinical development of a novel non-viral TRAC-knocked-in T cell therapy for the treatment of p53 R175H-mutant solid tumors.

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Retrieved on: 
Lunedì, Marzo 18, 2024
Research, Technology, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Other Science, Lymphoma, Patient, GBM, Artificial intelligence, Brain, Metadata, Pancreatic cancer, Lung cancer, Mantle cell lymphoma, Clinical trial, Therapy, Harmonic, ATM, USD, PD-1, MCL, DHL, Central nervous system, CNS, DNA, Starlight, Fox Chase Cancer Center, Glioblastoma, Cancer, Safety, Liquid biopsy, Calendar, ADC, TP53, NSCLC, ATRT, AI, AACR, Drug development, Machine learning, FDA, Annual general meeting, Incidence, Triple-negative breast cancer, NHL, Patent, Pharmaceutical industry

“This past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for our programs and our AI platform at Lantern Pharma.

Key Points: 
  • “This past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for our programs and our AI platform at Lantern Pharma.
  • During the 4th quarter of 2023, Lantern filed 3 new patent applications culminating in 11 new patent applications for the calendar year 2023.
  • The cash burn rate for the 4th quarter and full year of 2023 continues to reflect our capital-efficient, collaborator-centered business model.
  • Full Year Net Loss: Net loss per share was $1.47 per share for the fiscal year 2023 compared to $1.31 per share for the fiscal year 2022.

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

Retrieved on: 
Giovedì, Marzo 28, 2024
TP53, Innovation, Innovation Center station, Patient, Surface plasmon resonance, Artificial intelligence, Cancer, Allele, HLA, CK Life Sciences, AACR, Robotics, MHC, MHC-II, Therapy, Cosmetics, Data, Probability, Peptide, Vaccine

The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.

Key Points: 
  • The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.
  • "We are excited to share the progress from our joint research initiative with CK Life Sciences, which leverages the innovative approach from our peptide R&D platform to design cancer vaccines with enhanced efficacy.
  • Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation.
  • The peptide R&D platform can carry out high-precision AI peptide design and has successfully built data-driven design processes for both linear and cyclic peptides.

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

Retrieved on: 
Giovedì, Marzo 28, 2024
TP53, Innovation, Innovation Center station, Patient, Surface plasmon resonance, Artificial intelligence, Cancer, Allele, HLA, CK Life Sciences, AACR, Robotics, MHC, MHC-II, Therapy, Cosmetics, Data, Probability, Peptide, Vaccine

The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.

Key Points: 
  • The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.
  • "We are excited to share the progress from our joint research initiative with CK Life Sciences, which leverages the innovative approach from our peptide R&D platform to design cancer vaccines with enhanced efficacy.
  • Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation.
  • The peptide R&D platform can carry out high-precision AI peptide design and has successfully built data-driven design processes for both linear and cyclic peptides.

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Giovedì, Febbraio 29, 2024
Research, Autoimmune disease, Anemia, Investment, Lung cancer, Patient, Mirvetuximab soravtansine, PLD, Cancer cell, AZA, Azacitidine, Neoplasm, Clinical trial, TP53, Fusion, Autoimmunity, G&A, Cancer research, NSCLC, AML, ASH, Inflammation, Conference, Safety, Collaboration, Pharmacokinetics, Insurance, Messenger, Research and development, Society, Event, Administration, Citigroup, Publication, Cancer, Pharmaceutical industry

Initial combination data from the Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in PROC expected mid-year 2024.

Key Points: 
  • Initial combination data from the Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in PROC expected mid-year 2024.
  • Shattuck Closes Financing: On December 21, 2023, Shattuck announced a $50 million public offering of common stock and concurrent private placement of pre-funded warrants.
  • Research and Development (R&D) Expenses: R&D expenses for the quarter ended December 31, 2023, were $15.2 million, as compared to $21.9 million for the quarter ended December 31, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the quarter ended December 31, 2023 were $4.4 million, as compared to $4.8 million for the quarter ended December 31, 2022.

DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology

Retrieved on: 
Venerdì, Marzo 8, 2024
Oncology, Health, Stem Cells, Genetics, General Health, Research, Science, Skin cancer, DMT, NPV, MD, Melanoma, Skin, TP53, Paul Khavari, AAD, NOTCH1, Abstract, Patient, Journal, Trial of the century, DNA, American Academy

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.

Key Points: 
  • DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.
  • “This real-world clinical study demonstrates that the DMT can help clinicians improve outcomes for cutaneous melanomas in patients of all skin types,” commented Dr. Skelsey.
  • The research found that somatic mutations in healthy-appearing sun-exposed skin indicate an increased risk for skin cancer.
  • Furthermore, these mutations capture skin cancer risk information that is not accounted for by other risk factors.

Revolutionary Elephant iPSC Milestone Reached in Colossal’s Woolly Mammoth Project

Retrieved on: 
Mercoledì, Marzo 6, 2024
Biotechnology, Technology, Health, Environmental Issues, Environmental Health, Other Science, Research, Software, Genetics, Environment, Science, Hoechst, KLF4, CRISPR, Woolly mammoth, Multimedia, Cattle, Growth, Harvard University, Cell, Developmental biology, TP53, Gametogenesis, Colossal Biosciences, Factorization of polynomials, Life, Elephant, IPSC, MYC, Cat, Genome, Gene, OCT4, Rhinoceros, Publication, PCR, Biology, Cancer, Hunting

Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough.

Key Points: 
  • Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced pluripotent stem cells) breakthrough.
  • This milestone advancement was one of the primary early goals of the mammoth project, and supports the feasibility of future multiplex ex utero mammoth gestation.
  • Invaluable for Colossal’s Woolly Mammoths, these cells can be multiplex-edited and differentiated to study cold adaptation traits like woolly hair growth and fat storage in cellular and organoid models.
  • “In the past, a multitude of attempts to generate elephant iPSCs have not been fruitful.

Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation from U.S. FDA for the Treatment of Acute Myeloid Leukemia

Retrieved on: 
Martedì, Febbraio 20, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Pharmacy, Senior, AML, Fast track (FDA), SVP, Marketing, FDA, Partnership, Food, TP53, Regulatory affairs, MBA, Doctor of Pharmacy, PLK4, Rutgers University, University, Therapy, Patient, Survival, Diagnosis, Acute myeloid leukemia, Cancer, Pharmaceutical industry

Ocifisertib is currently being evaluated in a Phase 1b/2 study in adults with relapsed/refractory AML following standard of care therapy.

Key Points: 
  • Ocifisertib is currently being evaluated in a Phase 1b/2 study in adults with relapsed/refractory AML following standard of care therapy.
  • Orphan drug designation is granted by the FDA to drugs intended for treatment, prevention or diagnosis of a rare disease or condition that affects fewer than 200,000 people in the U.S. at the time of designation.
  • “The FDA’s decision to grant orphan drug designation, along with the previous FDA Fast Track designation for ocifisertib underscores Treadwell’s dedication to addressing this patient population with few treatment options.
  • Her leadership will be invaluable to Treadwell as we advance ocifisertib into potentially pivotal studies in 2025.”